Zolbetuximab 300mg Injection$2,200.00
1–9 boxes
$2,200.00 each
10–24 boxes
8% off
25+ boxes
10% off
Zolbetuximab 300mg Injection
SKU GME1101Oncology Care
Product Introduction
Zolbetuximab 300mg is a targeted antibody treatment for selected advanced stomach or gastro-oesophageal junction adenocarcinomas. It is used with fluoropyrimidine- and platinum-containing chemotherapy when the tumour is CLDN18.2-positive and HER2-negative.
How to use
The vial powder is reconstituted and diluted by the infusion team, then administered into a vein. Anti-sickness medicines are given before each infusion, and the infusion rate is adjusted for tolerance. The starting dose and later doses are calculated from body-surface area.
How it works
Zolbetuximab binds to claudin 18.2 on the surface of suitable tumour cells. This helps immune cells and complement proteins recognise and destroy those cells.
Side effects
Nausea, vomiting, reduced appetite, fatigue and infusion reactions can occur. Chemotherapy given alongside it can also cause low blood counts. Severe vomiting, dizziness, wheezing, facial swelling or difficulty breathing during infusion needs immediate treatment.
Important information
Tumour testing for CLDN18.2 and HER2 is necessary to identify suitable treatment. Existing nausea or vomiting is controlled before an infusion because this treatment can worsen both. Hydration and electrolyte replacement may be needed if vomiting is prolonged.
Uses
- First-line combination treatment of locally advanced unresectable or metastatic HER2-negative, CLDN18.2-positive gastric or gastro-oesophageal junction adenocarcinoma.
Benefits
Adding the antibody to an appropriate chemotherapy regimen can delay progression and improve survival in the biomarker-selected cancer population. The benefit depends on tumour eligibility rather than the location of the cancer alone.
Is this treatment suitable for every stomach cancer?
No. The tumour must meet the CLDN18.2-positive and HER2-negative criteria, as well as the disease-stage and treatment-history requirements for the combination.
Why is albumin measured during zolbetuximab treatment?
Albumin, a protein in the blood, can fall during zolbetuximab treatment with chemotherapy. Measuring it helps assess changes in protein status, particularly when appetite is poor or swelling develops.
Why are anti-sickness medicines given before symptoms start?
Nausea and vomiting are particularly important with this antibody, especially during early infusions. Preventive medicines reduce their severity and help avoid treatment interruption.
Does an infusion reaction always mean treatment must end permanently?
Management depends on severity. Some reactions permit a pause and slower restart, while severe allergy requires stopping the infusion and urgent treatment.
CLDN18.2: claudin protein used as a tumour-treatment target. HER2-negative: tumour without the relevant HER2 overexpression. Adenocarcinoma: cancer arising from gland-forming cells. Biomarker: measurable feature helping select treatment. Body-surface area: body-size calculation used for some infusion doses.; AR: Zolbetuximab 300mg حقن; FR: Zolbetuximab 300mg préparation injectable; PT: Zolbetuximab 300mg injetável; ES: Zolbetuximab 300mg inyectable; RU: Zolbetuximab 300mg инъекционная форма; ID: Zolbetuximab 300mg injeksi; VI: Zolbetuximab 300mg thuốc tiêm; MS: Zolbetuximab 300mg suntikan; TL: Zolbetuximab 300mg iniksyon; ZH-SG: Zolbetuximab 300mg 注射剂